- Home
- GWRS vs RLMD Comparison
GWRS vs RLMD Comparison
Compare GWRS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GWRS | RLMD |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.4M | 307.3M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | GWRS | RLMD |
|---|---|---|
| Price | $8.74 | $4.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 77.5K | ★ 1.2M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $55,468,000.00 | N/A |
| Revenue This Year | $8.18 | N/A |
| Revenue Next Year | $8.38 | N/A |
| P/E Ratio | $51.93 | ★ N/A |
| Revenue Growth | ★ 7.06 | N/A |
| 52 Week Low | $8.28 | $0.24 |
| 52 Week High | $13.35 | $5.12 |
Technical Indicators
Market Signals| Indicator | GWRS | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 62.48 |
| Support Level | $8.38 | $3.86 |
| Resistance Level | $8.65 | $4.56 |
| Average True Range (ATR) | 0.32 | 0.56 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 29.87 | 42.82 |
Price Performance
Historical ComparisonAbout GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.